Amicus Therapeutics Announces Public Offering of Common Stock
May 29 2019 - 4:14PM
Amicus Therapeutics (Nasdaq: FOLD) today announced it has commenced
a $150 million underwritten public offering of its common stock.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and
SVB Leerink LLC are acting as joint book-running managers for the
proposed offering. The Company expects to grant the underwriters a
30-day option to purchase up to an additional 15% of the shares of
common stock offered in the public offering. The offering is
subject to market conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the final
size or terms of the offering.
The Company expects to use the net proceeds of the offering for
investment in the development of the expanded gene therapy
pipeline, manufacturing capabilities for Pompe biologic AT-GAA and
gene therapy product candidates, including contract manufacturing
partnerships, completion of the design and build of the Amicus
Process Science and Gene Therapy Manufacturing facility and for
other general corporate and product development purposes.
The securities described above are being offered by Amicus
pursuant to a registration statement previously filed with the U.S.
Securities and Exchange Commission (the “SEC”) on April 24, 2019,
which became automatically effective upon the filing thereof.
A preliminary prospectus supplement relating to the offering will
also be filed with the SEC. Copies of the preliminary
prospectus supplement and accompanying base prospectus relating to
the offering may be obtained by contacting J.P. Morgan Securities
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717 (telephone number: 866-803-9204), Goldman
Sachs & Co. LLC, by mail, Attn: Prospectus Department, 200 West
Street, New York, NY 10282, by facsimile: 212-902-9316, by email:
prospectus-ny@ny.email.gs.com; or by telephone: 866-471-2526 or SVB
Leerink LLC, Attention: Syndicate Department, One Federal Street,
37th Floor, Boston, Massachusetts 01220, telephone: 1-800-808-7525,
ext. 6132 or email at syndicate@svbleerink.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Amicus TherapeuticsAmicus Therapeutics
(Nasdaq: FOLD) is a global, patient-dedicated biotechnology company
focused on discovering, developing and delivering novel
high-quality medicines for people living with rare metabolic
diseases. With extraordinary patient focus, Amicus
Therapeutics is committed to advancing and expanding a robust
pipeline of cutting-edge, first- or best-in-class medicines for
rare metabolic diseases.
Forward-Looking StatementsStatements regarding
the proposed public offering constitute forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. There can
be no assurance that Amicus will be able to complete the proposed
offering of common stock on acceptable terms, or at all.
Actual results or events may differ materially from those indicated
by forward-looking statements as a result of various risks,
uncertainties and important factors, including those set forth in
the “Risk Factors” section in the preliminary prospectus supplement
relating to the offering. In addition, all forward-looking
statements are subject to other risks detailed in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2018,
and Quarterly Report on Form 10-Q for the quarter ended March 31,
2019. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, and Amicus undertakes no
obligation to revise or update this news release to reflect events
or circumstances after the date hereof.
CONTACTS:
Investors/Media:Amicus TherapeuticsSara
Pellegrino, IRCVice President, Investor Relations & Corporate
Communicationsspellegrino@amicusrx.com (609) 662-5044
Media:Amicus TherapeuticsMarco WinklerDirector,
Corporate Communicationsmwinkler@amicusrx.com(609) 662-2798
FOLD–G
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Sep 2023 to Sep 2024